Statin therapy primary prevention vs Statin therapy secondary prevention
How to tell Statin therapy primary prevention and Statin therapy secondary prevention apart when a board question makes them look alike.
Step 2 CK pairs are in open beta while clinical review finishes. Spot an issue? Tell us.
Presence of prior clinical ASCVD event.
Side by side
Primary prevention uses calculated ASCVD risk, diabetes status, LDL level, and risk enhancers in patients without established ASCVD.
Secondary prevention applies to established ASCVD and generally requires high-intensity statin unless contraindicated.
Reducing LDL in at-risk but event-free patients lowers first cardiovascular event probability over time.
Aggressive LDL reduction after clinical ASCVD lowers recurrent plaque events and mortality.
Primary prevention decisions use fasting lipid profile and 10-year ASCVD risk estimation, with LDL 190 mg/dL or higher generally treated regardless of calculator output.
Secondary prevention follows prior MI, stroke, or symptomatic PAD history with goal of substantial LDL reduction, often 50% or greater using high-intensity statin therapy.
The trap
Using risk calculators in known ASCVD delays treatment intensity. Once clinical ASCVD is present, secondary prevention pathway supersedes primary risk-threshold debates.
The repair move
Next best step: for established ASCVD, start high-intensity statin such as atorvastatin 40 to 80 mg daily or rosuvastatin 20 to 40 mg daily, then reassess LDL response and add nonstatin therapy when targets remain above guideline thresholds.
Try a free question
CoreA 62-year-old woman without prior cardiovascular events has LDL 165 mg/dL and elevated 10-year ASCVD risk. What prevention category is this?
Show answer and explanation
Answer: B. Primary prevention. Absence of prior clinical ASCVD defines this as primary prevention stratification.
Why the other choices are tempting
- A. Incorrect because secondary prevention requires established clinical ASCVD history.
- C. Incorrect because this patient clearly requires preventive cardiovascular risk assessment.
- D. Incorrect because palliative framing does not apply to standard lipid prevention care.
- E. Incorrect because acute coronary syndrome management is not the current scenario.
Flashcards
Tap a card to flip it.
What finding immediately places a patient into statin secondary prevention?
Documented clinical ASCVD such as prior MI, ischemic stroke, or symptomatic PAD.
What framework guides statin use in patients without known ASCVD?
Primary prevention uses LDL level, diabetes status, and estimated 10-year ASCVD risk.
Quick answers
What is the fastest way to tell Statin therapy primary prevention from Statin therapy secondary prevention?
Presence of prior clinical ASCVD event.
What is the key clue for Statin therapy primary prevention?
Primary prevention uses calculated ASCVD risk, diabetes status, LDL level, and risk enhancers in patients without established ASCVD.
What is the key clue for Statin therapy secondary prevention?
Secondary prevention applies to established ASCVD and generally requires high-intensity statin unless contraindicated.
What is the common trap with Statin therapy primary prevention vs Statin therapy secondary prevention?
Using risk calculators in known ASCVD delays treatment intensity. Once clinical ASCVD is present, secondary prevention pathway supersedes primary risk-threshold debates.